Oncology Venture A/S Issues 1,619,912 Shares in Exchange for Previously Annulled Warrants

On October 6, 2020 Oncology Venture A/S ("OV" or the "Company") reported that a small group of recipients has received a total of 1,619,912 shares in Oncology Venture A/S (Press release, Oncology Venture, OCT 6, 2020, View Source [SID1234568159]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The share issue was announced on 21 August 2020 and concerns warrants of certain OV employees, board members, and consultants who were previous holders of warrants in Oncology Venture Sweden AB. These warrants have since been annulled, and the share issue announced today concludes the related clean-up of the obligations related to this annulment, incurred prior to departure of the prior management team.

Following the share issue, the registered share capital of Oncology Venture A/S is nominal DKK 9,668,713.15 divided into 193,374,263 shares of nominal DKK 0.05 each.

For additional information, please see the relevant press release announcing the issue published on 21 August 2020:

View Source

Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma

On October 6, 2020 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for TK216, an investigational potentially first-in-class targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, for treatment of Ewing sarcoma (Press release, Oncternal Therapeutics, OCT 6, 2020, View Source [SID1234568158]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the FDA’s rare pediatric disease designation and voucher program, the FDA may grant a priority review voucher to a sponsor who receives a product approval for a "rare pediatric disease," which is defined as a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and which either affects fewer than 200,000 people in the U.S., or affects more than 200,000 people in the U.S. but with no reasonable expectation that the cost of developing and making the drug available in the U.S. will be recovered from U.S. sales. Subject to FDA approval of TK216 for the treatment of Ewing sarcoma, Oncternal may be eligible to receive a priority review voucher if the marketing application submitted for the product satisfies certain additional conditions, including approval no later than September 30, 2022 (unless this statutory sunset provision is modified by Congress). If issued, this voucher may be redeemed to receive priority review for a subsequent marketing application or may be sold or transferred to another sponsor.

"The FDA’s rare pediatric disease designation of TK216 for treatment of Ewing sarcoma, for which Oncternal had previously received FDA’s Orphan Drug and Fast Track designations, underscores the agency’s recognition that Ewing sarcoma is a devastating cancer, with a high unmet medical need," said James Breitmeyer, M.D., Ph.D., President and CEO, Oncternal. "An expansion cohort in the clinical trial of TK216 for patients with relapsed/refractory Ewing sarcoma is currently enrolling, and we expect to present additional interim clinical data from our ongoing Phase 1 clinical trial at a scientific conference in the fourth quarter of 2020."

About Ewing sarcoma

Ewing sarcoma is the second most common bone tumor among children and adolescents. The median age at diagnosis of patients with Ewing sarcoma is 15, and the incidence is about 3 cases per 1 million per year in children under the age of 20 and about 1.3 cases per 1 million overall in the U.S. Nearly all Ewing sarcoma cases are driven by translocations of ETS family oncogenes, including 85-90% of cases driven by the EWS-FLI1 fusion, and approximately 10% by EWS-ERG. Patients diagnosed with metastatic disease have five-year survival rates between 18% and 30%. The prognosis for patients with recurrent Ewing sarcoma is particularly poor, and five-year survival after recurrence is approximately 10 to 15%.

About TK216

TK216 is an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins including fusion proteins. Tumorigenic fusion proteins involving the EWS protein and an ETS protein can be found in most cases of Ewing sarcoma. ETS-related translocations or overexpression are also found in many other tumors such as prostate cancer and acute myeloid leukemia (AML). TK216 was developed based on discoveries in the laboratory of Jeffrey Toretsky, M.D., at Georgetown Lombardi Comprehensive Cancer Center, who discovered inhibitors of EWS-FLI1 using a novel chemical screening assay. In preclinical models, TK216 was observed to bind to EWS-FLI1, blocking the interaction between this fusion protein and other transcriptome proteins such as RNA helicase A, leading to tumor cell apoptosis and inhibiting tumor growth in animal models. The U.S. Food and Drug Administration (FDA) has granted Orphan designation, Fast Track designation, and Rare Pediatric Disease designation to TK216 for the treatment of Ewing sarcoma. TK216 is an investigational medication that has not been approved by the FDA for any indication.

Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020

On October 6, 2020 Orion reported that it will publish Interim Report for January-September 2020 on Wednesday, 21 October 2020 approximately at 12.00 noon EEST (Press release, Orion , OCT 6, 2020, View Source [SID1234568157]). The report and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast and conference call

A webcast and a conference call for analysts, investors and media will be held on Wednesday, 21 October 2020 at 13.30 EEST. The event will be held only online and by conference call.

A link to the live webcast will be available on Orion’s website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.

Iovance Biotherapeutics to Present at Upcoming October Conferences

On October 6, 2020 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported that the company plans to present at the following conferences (Press release, Iovance Biotherapeutics, OCT 6, 2020, View Source [SID1234568156]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Cell Therapy Summit (VIRTUAL) | October 6, 2020
Date/Time: Tuesday, Oct. 6 at 3:00 p.m. EDT
Webcast: a live and archived webcast of the presentation will be available in the Investors section of the Iovance website at View Source
Alliance for Regenerative Medicine (ARM) Meeting on the Mesa (VIRTUAL) | October 12-16, 2020
Date/Time: presentation available on demand beginning Oct. 12, 2020, at View Source
A live and archived webcast of the presentation will be available in the Investors section of the Iovance website at View Source.

Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial

On October 6, 2020 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") reported that the University of Louisville and the Ochsner Clinic in New Orleans, Louisiana are now active trial sites in its Phase 1/2 Actimab-A venetoclax combination trial for patients with Relapsed or Refractory ("R/R") Acute Myeloid Leukemia ("AML") age 18 and above (Press release, Actinium Pharmaceuticals, OCT 6, 2020, View Source [SID1234568155]). These sites join UCLA Medical Center, where the trial is being led by Gary Schiller, MD, Professor, Hematology-Oncology and Director, Hematologic Malignancy/Stem Cell Transplant Program. Both sites participated in Actinium’s Phase 2 trial with Actimab-A as a single agent that produced remission rates as high as 69% with minimal non-hematologic toxicities in patients newly diagnosed with AML. The Phase 2 trial results together with a synergistic mechanism of action with venetoclax demonstrated in pre-clinical studies are driving this combination trial with an initial focus on the high unmet needs of R/R patients including those who have relapsed or do not respond to treatment with venetoclax based regimens.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Venetoclax is now a mainstay in the AML treatment armamentarium, but the lack of durable remissions, particularly in patients with relapsed or refractory disease who may not respond to venetoclax at all, is an area we are committed to addressing. Our pre-clinical data indicate that Actimab-A is synergistic with venetoclax in venetoclax-resistant cell lines and have documented a reduction of Mcl-1 as the mechanism. Our clinical trial seeks to demonstrate improved response rates and response durations without added toxicities with the combination of Actimab-A and venetoclax. Given the preclinical data, the targeted nature of Actimab-A, and the minimal non-hematologic toxicity profile, we think that the combination with venetoclax has great promise" said Dr. Mark Berger, Actinium’s Chief Medical Officer. Dr. Berger added, "We are delighted to once again be working with the University of Louisville and the Ochsner Clinic who were among the top enrolling sites in our Phase 2 single-agent Actimab-A trial. We look forward to activating additional sites on this important trial as we work to advance treatment options for patients with AML."

Actinium recently announced that the first dose cohort in the Phase 1 portion of the Actimab-A venetoclax combination trial has been complete and enrollment of the second dose cohort has been initiated. Actinium expects continued site additions and anticipates proof of concept results from the Phase 1 portion of the trial in 2021.

Rationale for Actimab-A Venetoclax Combination Trial

This Phase 1/2 trial is a multicenter, open label trial of Actimab-A (lintuzumab-Ac225) added to venetoclax for patients with CD33 positive relapsed/refractory (R/R) Acute Myeloid Leukemia. In a poster presentation at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019, Actimab-A was shown to be synergistic with venetoclax in venetoclax resistant cell lines, by depleting MCL-1, a protein shown to mediate resistance to venetoclax. The Phase 1 portion of the study is designed to determine the maximum tolerated dose (MTD) of Actimab-A added to venetoclax for R/R AML. The Phase 2 portion of the trial will assess the percentage of patients with Overall Response (CR + CRh) up to six months after the start of the treatment without receiving other AML therapies. The trial will enroll R/R AML patients who have been treated with venetoclax as well as venetoclax-naïve patients. At the 1.0 uCi/kg dose, Actimab-A is administered on Day 5 of each cycle for four cycles and venetoclax is taken on Days 1-21 of each cycle for up to 4 cycles. Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery. Gary Schiller, MD, Professor, Hematology-Oncology and Director, Hematologic Malignancy/Stem Cell Transplant Program at the UCLA Medical Center is the Principal Investigator for this study.